WO2001074386A3 - Cold-adapted equine influenza viruses - Google Patents

Cold-adapted equine influenza viruses Download PDF

Info

Publication number
WO2001074386A3
WO2001074386A3 PCT/US2001/008968 US0108968W WO0174386A3 WO 2001074386 A3 WO2001074386 A3 WO 2001074386A3 US 0108968 W US0108968 W US 0108968W WO 0174386 A3 WO0174386 A3 WO 0174386A3
Authority
WO
WIPO (PCT)
Prior art keywords
viruses
cold
equine influenza
influenza virus
influenza
Prior art date
Application number
PCT/US2001/008968
Other languages
French (fr)
Other versions
WO2001074386A2 (en
Inventor
Patricia W Dowling
Julius S Youngner
Original Assignee
Univ Pittsburgh
Patricia W Dowling
Julius S Youngner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh, Patricia W Dowling, Julius S Youngner filed Critical Univ Pittsburgh
Priority to CA002403979A priority Critical patent/CA2403979A1/en
Priority to JP2001572128A priority patent/JP2003528925A/en
Priority to AU4930001A priority patent/AU4930001A/en
Priority to DE60125736T priority patent/DE60125736D1/en
Priority to AU2001249300A priority patent/AU2001249300B2/en
Priority to EP01922507A priority patent/EP1267920B1/en
Priority to US10/239,972 priority patent/US7029903B2/en
Publication of WO2001074386A2 publication Critical patent/WO2001074386A2/en
Publication of WO2001074386A3 publication Critical patent/WO2001074386A3/en
Priority to US11/332,989 priority patent/US20060121521A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16164—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity, dominant interference, or attenuation. Such viruses are formulated into therapeutic compositions to protect animals from diseases caused by influenza A viruses, and in particular, to protect horses from disease caused by equine influenza virus. The present invention also includes methods to protect animals from diseases caused by influenza A virus or other infectious agents utilizing the claimed therapeutic compositions. Such methods include using a therapeutic composition as a vaccine to generate a protective immune response in an animal prior to exposure to an infectious agent, as well as using a therapeutic composition as a treatment for an animal that has been recently infected with an infectious agent leading to respiratory disease, or is likely to be subsequently exposed to such an agent in a few days whereby the therapeutic composition reduces such respiratory disease, even in the absence of antibody-mediated immunity. The present invention also provides methods to produce cold-adapted equine influenza viruses, and reassortant influenza A viruses having at least one genome segment of an equine influenza virus generated by cold-adaptation.
PCT/US2001/008968 2000-04-03 2001-03-21 Cold-adapted equine influenza viruses WO2001074386A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002403979A CA2403979A1 (en) 2000-04-03 2001-03-21 Cold-adapted equine influenza viruses
JP2001572128A JP2003528925A (en) 2000-04-03 2001-03-21 Cold adapted equine influenza virus
AU4930001A AU4930001A (en) 2000-04-03 2001-03-21 Cold-adapted equine influenza viruses
DE60125736T DE60125736D1 (en) 2000-04-03 2001-03-21 COMPOSITIONS CONTAINING COLD ADAPTED HORSE INFLUENZA VIRUSES FOR THE TREATMENT OF EXISTING VIRUS INFECTIONS OF THE BREATHING SYSTEM
AU2001249300A AU2001249300B2 (en) 2000-04-03 2001-03-21 Cold-adapted equine influenza viruses
EP01922507A EP1267920B1 (en) 2000-04-03 2001-03-21 Compositions comprising cold-adapted equine influenza viruses for the treatment of existing viral infections of the respiratory system.
US10/239,972 US7029903B2 (en) 2000-04-03 2001-03-21 Cold-adapted equine influenza viruses
US11/332,989 US20060121521A1 (en) 2000-04-03 2006-01-17 Cold-adapted equine influenza viruses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19432500P 2000-04-03 2000-04-03
US60/194,325 2000-04-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/332,989 Continuation US20060121521A1 (en) 2000-04-03 2006-01-17 Cold-adapted equine influenza viruses

Publications (2)

Publication Number Publication Date
WO2001074386A2 WO2001074386A2 (en) 2001-10-11
WO2001074386A3 true WO2001074386A3 (en) 2002-05-23

Family

ID=22717146

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/008968 WO2001074386A2 (en) 2000-04-03 2001-03-21 Cold-adapted equine influenza viruses

Country Status (8)

Country Link
US (2) US7029903B2 (en)
EP (1) EP1267920B1 (en)
JP (1) JP2003528925A (en)
AT (1) ATE350056T1 (en)
AU (2) AU2001249300B2 (en)
CA (1) CA2403979A1 (en)
DE (1) DE60125736D1 (en)
WO (1) WO2001074386A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004003572A1 (en) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunity inducers based on attenuated rabbit myxomaviruses
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
EP2391713A1 (en) 2009-01-30 2011-12-07 The Board Of Regents For Oklahoma State University Immunogenic compositions, vaccines and diagnostics based on canine distemper viruses circulating in north american dogs
CN107375919B (en) 2009-03-27 2022-07-29 台湾地区“中央研究院” Methods and compositions for antiviral immunity
KR20130018681A (en) * 2010-03-10 2013-02-25 인터벳 인터내셔널 비.브이. Method for protecting against disease caused by secondary pathogens
TWI537385B (en) 2010-11-04 2016-06-11 中央研究院 Methods for producing virus particles with simplified glycosylation of surface proteins
CN104411330B (en) * 2012-05-31 2017-02-22 佐蒂斯有限责任公司 Vaccination with canine respiratory coronavirus for protection against b. bronchiseptica infections
JP6560056B2 (en) * 2015-08-07 2019-08-14 ウィスコンシン アルムニ リサーチ ファンデイション H3 equine influenza A virus
JP2018088928A (en) * 2018-02-13 2018-06-14 ウィスコンシン アルムニ リサーチ ファンデイション H3 equine influenza a virus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009702A1 (en) * 1998-08-13 2000-02-24 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3518347A (en) * 1965-05-28 1970-06-30 Inst Microbiologie Et D Hygien Vaccine for equine influenza
US3992522A (en) * 1973-01-24 1976-11-16 The United States Of America As Represented By The Department Of Health, Education And Welfare Temperature-sensitive recombinant mutant viruses and a process for producing same
WO1983003546A1 (en) 1982-04-16 1983-10-27 Cornell Res Foundation Inc Temperature sensitive reassortant viruses and a vaccine against equine influenza
US4683137A (en) * 1982-04-16 1987-07-28 Cornell Research Foundation, Inc. Temperature sensitive reassortant viruses and a vaccine against equine influenza
GB8300467D0 (en) * 1983-01-08 1983-02-09 Wellcome Found Equine influenza
US4631191A (en) * 1985-06-20 1986-12-23 Biotechnology Research Partners, Ltd. Methods and compositions useful in preventing equine influenza
US4920213A (en) * 1985-06-20 1990-04-24 Biotechnology Research Partners, Ltd. Method and compositions useful in preventing equine influenza
US5149531A (en) * 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Attenuated respiratory syncytial virus vaccine compositions
US5690937A (en) * 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009702A1 (en) * 1998-08-13 2000-02-24 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAYR A: "[Respiratory infectious diseases in horses]. Respiratorische Infektionskrankheiten beim Pferd.", TIERARZTLICHE PRAXIS. SUPPLEMENT, (1987) 2 1-4. REF: 0, 1987, XP001015771 *
TIMONEY P J: "Equine influenza.", COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES, vol. 19, no. 3, 1996, pages 205 - 211, XP001015825, ISSN: 0147-9571 *

Also Published As

Publication number Publication date
CA2403979A1 (en) 2001-10-11
DE60125736D1 (en) 2007-02-15
AU4930001A (en) 2001-10-15
WO2001074386A2 (en) 2001-10-11
US7029903B2 (en) 2006-04-18
JP2003528925A (en) 2003-09-30
EP1267920B1 (en) 2007-01-03
AU2001249300B2 (en) 2006-02-16
US20040223980A1 (en) 2004-11-11
EP1267920A2 (en) 2003-01-02
ATE350056T1 (en) 2007-01-15
US20060121521A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
ATE358722T1 (en) COLD-ADAPTABLE HORSES INFLUENZA VIRUSES
WO2001060849A3 (en) Cold-adapted equine influenza viruses
TW200730188A (en) Vaccines and methods to treat canine influenza
WO2001074386A3 (en) Cold-adapted equine influenza viruses
ATE451119T1 (en) SUBUNITY VACCINE AGAINST RESPIRATORY SYNZYTIAL VIRUS
MXPA02004627A (en) Vaccines for mycoplasma bovis.
DE60130998D1 (en) RIBAVIRIN-CONTAINING VACCINE
WO2007098717A3 (en) Chimeric vaccine antigens against classical swine fever virus
WO2007036735A3 (en) Immunogenic agents againts burkholderia psudomallei and/or burkholderia mallei, comprising lipopolysaccharide, capsular polysaccharide and/or proteins from burkholderia psuedomallei
WO2004043404A3 (en) Process for designing inhibitors of influenza virus non-structural protein 1
MXPA03009763A (en) Foot and mouth disease virus vaccine.
WO1999053950A3 (en) Live vaccines and methods of treatment therewith
WO2005084315A3 (en) Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease
JP2003528925A5 (en)
Dowling et al. Cold-adapted equine influenza viruses
WO2007135420A3 (en) Defective interfering virus
HUP9700975A2 (en) Live attenuated rtx-producing bacteria of the family pasteurellaceae
YU65102A (en) In ovo protection against infectious bronchitis
TW200503755A (en) Avian vaccine composition for the protection of poultry against disease and infection caused by e. coli and salmonella
DK1132466T3 (en) Chicken anemia virus with low pathogenicity
Thomson et al. Foot and Mouth Disease in Southern Africa: Re-evaluation of the approach to control
WO2002081712A3 (en) Artificial chromosomes comprising ehv sequences
NO20014372D0 (en) Isolation and partial characterization of a novel antiprocferative component from human leukocytes
Bensaude et al. 40. Interactions between Classical swine fever virus and host cells
Holliman 38. Foot and mouth disease in Cumbria—a day in the life

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001249300

Country of ref document: AU

Ref document number: 2403979

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001922507

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 572128

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10239972

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001922507

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001922507

Country of ref document: EP